Niki BioSolutions, Inc. (NIKI)
NASDAQ: NIKI · Real-Time Price · USD
8.38
-0.20 (-2.33%)
At close: Jul 24, 2026, 4:00 PM EDT
8.03
-0.35 (-4.18%)
After-hours: Jul 24, 2026, 7:59 PM EDT
Niki BioSolutions Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1
Market Cap
6.82M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 431.38K | -864.51K | -66.71% |
| Dec 31, 2022 | 1.30M | -245.89K | -15.95% |
| Dec 31, 2021 | 1.54M | 630.27K | 69.15% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNIKI News
- 10 days ago - Aptorum Group Provides Update on DiamiR Biosciences Merger - GlobeNewsWire
- 18 days ago - Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer's Association International Conference - GlobeNewsWire
- 4 weeks ago - Aptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer's Disease Biomarkers - GlobeNewsWire
- 5 weeks ago - Statement in Response to Silver Elephant's News Release Dated June 17, 2026 - Newsfile Corp
- 6 weeks ago - Aptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR Biosciences - GlobeNewsWire
- 4 months ago - Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania - GlobeNewsWire
- 6 months ago - Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB's Automated APOE Testing Platform for Alzheimer's Disease - GlobeNewsWire
- 8 months ago - DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference - GlobeNewsWire